Proactive Investors
09 Jun 2026, 06:50 UTC · 2h ago
Imaging Biometrics sees encouraging Phase 1 trial data
Proactive Investors
09 Jun 2026, 06:50 UTC · 2h ago
Story key points
3 claims · impact-rated
Imaging Biometrics' Phase 1 trial of oral gallium maltolate for recurrent glioblastoma showed the treatment was safe and well tolerated with no Grade 3 or higher toxicities. — Positive safety and tolerability data in a first-in-human trial reduce clinical risk and justify progression to Phase 2.
+0.40KEFI Gold and Copper has secured a US$20 million equity-ranking royalty, completing its US$340 million funding package for the Tulu Kapi gold project. — Full funding of a major project removes a significant financial hurdle and allows operational execution to proceed.
+0.30Imaging Biometrics reported a median overall survival of 16 months for 22 evaluable patients in its gallium maltolate trial. — While the study was not powered for efficacy, these early survival figures provide a positive signal for further development.
+0.20Ticker attribution
Continue reading
6 related stories
Top 1 mover · tap to explore
Model heads
Positive Phase 1 results for oral gallium maltolate in glioblastoma show the treatment is safe and well tolerated.
Secured an additional $20 million royalty, completing the funding package for the Tulu Kapi gold project.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Zacks Investment Research
16h ago
